S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10
S&P 500   4,326.51
DOW   34,160.78
QQQ   341.10

ProQR Therapeutics Stock Forecast, Price & News

-0.09 (-1.76%)
(As of 01/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
420,482 shs
Average Volume
537,105 shs
Market Capitalization
$252.53 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ProQR Therapeutics logo

About ProQR Therapeutics

ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Its product pipeline include Sepofarsen, QR-421a, QR-1123, and QR-504a. The company was founded by Daniel de Boer, Gerard Platenburg, Henri Termeer, and Dinko Valerio on February 21, 2012 and is headquartered in Leiden, the Netherlands.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$10.80 million
Book Value
$1.29 per share


Net Income
$-53.19 million
Net Margins
Pretax Margin




Free Float
Market Cap
$252.53 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.91 out of 5 stars

Medical Sector

721st out of 1,417 stocks

Pharmaceutical Preparations Industry

350th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

Is ProQR Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ProQR Therapeutics stock.
View analyst ratings for ProQR Therapeutics
or view top-rated stocks.

How has ProQR Therapeutics' stock price been impacted by Coronavirus?

ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PRQR stock has decreased by 28.1% and is now trading at $5.03.
View which stocks have been most impacted by COVID-19

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 1,210,000 shares, an increase of 45.2% from the December 31st total of 833,400 shares. Based on an average trading volume of 380,100 shares, the short-interest ratio is currently 3.2 days. Approximately 2.5% of the shares of the stock are short sold.
View ProQR Therapeutics' Short Interest

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for ProQR Therapeutics

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics (NASDAQ:PRQR) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.01. The biopharmaceutical company earned $1.03 million during the quarter, compared to the consensus estimate of $0.80 million. ProQR Therapeutics had a negative trailing twelve-month return on equity of 65.00% and a negative net margin of 3,747.12%.
View ProQR Therapeutics' earnings history

What price target have analysts set for PRQR?

6 brokers have issued twelve-month target prices for ProQR Therapeutics' stock. Their forecasts range from $17.00 to $44.00. On average, they expect ProQR Therapeutics' share price to reach $26.14 in the next twelve months. This suggests a possible upside of 419.7% from the stock's current price.
View analysts' price targets for ProQR Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the following people:
  • Daniel Anton de Boer, Chief Executive Officer
  • Smital Shah, Chief Financial & Business Officer
  • Aniz Girach, Chief Medical Officer
  • Jennifer Pluim, Vice President-Medical Affairs
  • Naveed K. Shams, Chief Scientific Officer

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include (BIOA) (BIOA), Galapagos (GLPG), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), uniQure (QURE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Franklin Street Advisors Inc. NC (0.22%), Belvedere Trading LLC (0.00%), Brown Advisory Inc. (0.04%) and Dorsey Wright & Associates (0.01%).

Which major investors are buying ProQR Therapeutics stock?

PRQR stock was acquired by a variety of institutional investors in the last quarter, including Belvedere Trading LLC, Brown Advisory Inc., Franklin Street Advisors Inc. NC, and Dorsey Wright & Associates.

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $5.03.

How much money does ProQR Therapeutics make?

ProQR Therapeutics has a market capitalization of $252.53 million and generates $10.80 million in revenue each year. The biopharmaceutical company earns $-53.19 million in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does ProQR Therapeutics have?

ProQR Therapeutics employs 1,504 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is www.proqr.com.

Where are ProQR Therapeutics' headquarters?

ProQR Therapeutics is headquartered at Zernikedreef 9, Leiden P7, 2333 CK.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at (188) 166-7000 or via email at [email protected].

This page was last updated on 1/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.